In vitro evaluation of the effect of Ceftiofur Sodium and of a new Gentamycin Sulfate formulation on the viability of Marek disease virus

TL;DR

This study in vitro assessed the impact of gentamicin sulfate and ceftiofur sodium on Marek's disease virus viability, finding minimal effects on vaccine titers and confirming safety for use with the vaccine.

Contribution

It provides new data on the safety of these antibiotics when used with Marek's disease vaccine, showing they do not significantly reduce vaccine efficacy.

Findings

Gentamicin sulfate and ceftiofur sodium do not significantly reduce vaccine titers.

Antibiotics do not alter pH or significantly affect virus viability within 60 minutes.

Vaccine titers remain above protective levels despite antibiotic exposure.

Abstract

The present study evaluated In vitro effect of gentamicin sulfate and ceftiofur sodium on the viability of the Marek's disease virus. The titer of cell associated turkey herpesvirus (HVT) vaccine was not appreciably reduced when incubated with 50 mg/ml of gentamicin sulfate or ceftiofur sodium. Statistic difference was not found between the number of plaqueforming units (PFU) of reconstituted vaccine associated with both antibiotics 0, 15, 30 and 60 minutes after reconstitution of vaccine. The antibiotics did not considerably alter the pH values. There was a significative decrease of the titer of all vaccinal solutions when they were inoculated 30 and 60 minutes after the reconstitution of the vaccine. Nevertheless, these titers are higher than the required titers to protectect against the Marek disease.